JP2000500492A - Ob蛋白組成物を用いる非脂肪組織重増加方法 - Google Patents
Ob蛋白組成物を用いる非脂肪組織重増加方法Info
- Publication number
- JP2000500492A JP2000500492A JP9519745A JP51974597A JP2000500492A JP 2000500492 A JP2000500492 A JP 2000500492A JP 9519745 A JP9519745 A JP 9519745A JP 51974597 A JP51974597 A JP 51974597A JP 2000500492 A JP2000500492 A JP 2000500492A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- amino acids
- analog
- subitem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 非脂肪組織重増加方法において、 (a)配列番号2または配列番号4に示したアミノ酸配列1〜146; (b)位置35にリジン残基と位置74にイソロイシン残基を有する配列番号 4に示したアミノ酸配列群1〜146; (c)位置4、8、32、33、35、48、50、53、60、64、66 、67、68、71、74、77、78、89、97、100、102、105 、106、107、108、111、112、118、136、138、142 および145(配列番号4による番号割り付けを使用)のうちの1以上において 異なるアミノ酸による置換がある上記下位項目(b)のアミノ酸配列; (d)位置28のグルタミン残基が欠失していても良い上記下位項目(a)、 (b)または(c)のアミノ酸配列; (e)N末端にメチオニン残基を有する上記下位項目(a)、(b)、(c) または(d)のアミノ酸配列; (f)(位置35にリジン残基と位置74にイソロイシン残 基を有する配列番号4の番号割り付けを使用して) (i)アミノ酸98〜146 (ii)アミノ酸1〜32 (iii)アミノ酸40〜116 (iv)アミノ酸1〜99および112〜146 (v)アミノ酸99と112の間にアミノ酸100〜111の1以上がその 順序で存在するアミノ酸1〜99および112〜146; (vi)アミノ酸100、102、105、106、107、108、11 1、112、118、136、138、142および145のうちの1以上が別 のアミノ酸によって置換されている上記下位項目(f)(i)の切断OB類縁体 ; (vii)アミノ酸4、8および32のうちの1以上が別のアミノ酸によっ て置換されている上記下位項目(f)(ii)の切断類縁体; (viii)アミノ酸50、53、60、64、66、67、68、71、 74、77、78、89、97、100、102、105、106、107、1 08、111および112のうちの1以上が別のアミノ酸によって置換されてい る上記下位項目 (f)(iii)の切断類縁体; (vix)アミノ酸4、8、32、33、35、48、50、53、60、 64、66、67、68、71、74、77、78、89、97、112、11 8、136、138、142および145のうちの1以上が別のアミノ酸によっ て置換されている上記下位項目(f)(iv)の切断類縁体; (x)アミノ酸4、8、32、33、35、48、50、53、60、64 、66、67、68、71、74、77、78、89、97、100、102、 105、106、107、108、111、112、118、136、138、 142および145のうちの1以上が別のアミノ酸によって置換されている上記 下位項目(f)(v)の切断類縁体; (xi)N末端メチオニン残基を有する上記下位項目(f)(i)〜(x) のいずれかの切断類縁体から選択される切断OB蛋白類縁体; (g)蛋白部分に連結した化学部分を有してなる上記下位項目(a)〜(f) のいずれかのOB蛋白もしくは類縁誘導体; (h)前記化学部分が水溶性ポリマー部分である上記下位項目(g)の誘導体 ; (i)前記水溶性ポリマー部分がポリエチレングリコールである上記下位項目 (h)の誘導体; (j)前記水溶性ポリマー部分がポリアミノ酸部分である上記下位項目(h) の誘導体; (k)前記水溶性ポリマー部分が前記蛋白部分のN末端のみに結合している上 記下位項目(h)の誘導体; (l)上記下位項目(a)〜(k)のいずれかのOB蛋白、類縁体もしくは誘 導体から選択される有効量のOB蛋白、該蛋白の類縁体もしくは誘導体が医薬的 に許容される担体に入ったものを投与する段階を有してなる方法。 2. 前記方法によって、インシュリンに対する感受性向上も得られる請求項1 に記載の方法。 3. 前記方法によって全身活力向上も得られる請求項1に記載の方法。 4. 前記方法によって、骨吸収低下も得られる請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56173295A | 1995-11-22 | 1995-11-22 | |
US08/561,732 | 1995-11-22 | ||
PCT/US1996/017718 WO1997018833A1 (en) | 1995-11-22 | 1996-11-04 | Methods of increasing lean tissue mass using ob protein compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001352728A Division JP4227325B2 (ja) | 1995-11-22 | 2001-11-19 | Ob蛋白組成物を用いる非脂肪組織重増加方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000500492A true JP2000500492A (ja) | 2000-01-18 |
JP4173914B2 JP4173914B2 (ja) | 2008-10-29 |
Family
ID=24243198
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51974597A Expired - Fee Related JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ob蛋白組成物を用いる非脂肪組織重増加方法 |
JP2001352728A Expired - Fee Related JP4227325B2 (ja) | 1995-11-22 | 2001-11-19 | Ob蛋白組成物を用いる非脂肪組織重増加方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001352728A Expired - Fee Related JP4227325B2 (ja) | 1995-11-22 | 2001-11-19 | Ob蛋白組成物を用いる非脂肪組織重増加方法 |
Country Status (15)
Country | Link |
---|---|
EP (3) | EP1285664B1 (ja) |
JP (2) | JP4173914B2 (ja) |
AT (2) | ATE259243T1 (ja) |
AU (3) | AU7607496A (ja) |
CA (2) | CA2236163A1 (ja) |
DE (2) | DE69631544T2 (ja) |
DK (1) | DK0866720T3 (ja) |
ES (2) | ES2217327T3 (ja) |
IL (2) | IL124442A0 (ja) |
MX (1) | MX9803992A (ja) |
NZ (3) | NZ512083A (ja) |
PT (1) | PT866720E (ja) |
SI (1) | SI0866720T1 (ja) |
WO (1) | WO1997018833A1 (ja) |
ZA (1) | ZA969605B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008150369A (ja) * | 1997-04-17 | 2008-07-03 | Amgen | 安定かつ活性なヒトOBタンパク質と抗体Fc鎖とのコンジュゲートを含む組成物および方法 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
ES2217327T3 (es) * | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
AU2246097A (en) * | 1996-01-25 | 1997-08-20 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
EP0917469A1 (en) * | 1996-04-19 | 1999-05-26 | ZymoGenetics, Inc. | Methods for inducing bone formation |
CA2274799A1 (en) * | 1996-12-20 | 1998-07-02 | Eli Lilly And Company | Anti-obesity proteins |
EA004790B1 (ru) * | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
EP0950417A3 (en) | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Treatment of skeletal disorders |
WO1999053939A1 (en) * | 1998-04-20 | 1999-10-28 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis with leptin |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
WO2000024418A1 (en) * | 1998-10-27 | 2000-05-04 | Eli Lilly And Company | Prevention of muscle mass loss with leptin receptor ligands |
WO2000047741A1 (en) * | 1999-02-12 | 2000-08-17 | Amgen Inc. | Glycosylated leptin compositions and related methods |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
DK1444516T3 (da) | 2001-10-22 | 2010-11-15 | Amgen Inc | Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
ES2390082T5 (es) * | 2004-06-30 | 2018-01-19 | Nektar Therapeutics | Conjugados de resto de Factor IX y polímeros |
ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
WO2008048691A2 (en) * | 2006-10-18 | 2008-04-24 | Amylin Pharmaceuticals, Inc. | Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders |
WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
LT2900230T (lt) | 2012-09-27 | 2019-01-10 | The Children`S Medical Center Corporation | Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai |
TR201901299T4 (tr) | 2013-11-26 | 2019-02-21 | Childrens Medical Ct Corp | Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri. |
US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
PT3509624T (pt) | 2016-09-12 | 2023-08-28 | Amryt Pharmaceuticals Inc | Métodos de deteção de anticorpos neutralizantes anti-leptina |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1228925B (it) * | 1987-08-07 | 1991-07-10 | Eniricerche Spa | Procedimento per la preparazione dell'ormone della crescita umano |
DK173142B1 (da) * | 1988-08-24 | 2000-02-07 | Natinco Nv | Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise |
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
DE4428146A1 (de) * | 1993-08-13 | 1995-02-16 | Putzmeister Maschf | Verfahren und Anordnung zur Oberflächenbearbeitung von Großobjekten |
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
ES2217327T3 (es) * | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
RU2178307C2 (ru) * | 1995-12-27 | 2002-01-20 | Джинентех Инк. | Производные ов-протеина |
EA004790B1 (ru) * | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
CA2286098C (en) * | 1997-04-17 | 2009-07-07 | Amgen Inc. | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
-
1996
- 1996-11-04 ES ES96938773T patent/ES2217327T3/es not_active Expired - Lifetime
- 1996-11-04 WO PCT/US1996/017718 patent/WO1997018833A1/en active IP Right Grant
- 1996-11-04 ES ES02011474T patent/ES2339846T3/es not_active Expired - Lifetime
- 1996-11-04 EP EP02011474A patent/EP1285664B1/en not_active Expired - Lifetime
- 1996-11-04 NZ NZ512083A patent/NZ512083A/xx not_active IP Right Cessation
- 1996-11-04 DK DK96938773T patent/DK0866720T3/da active
- 1996-11-04 PT PT96938773T patent/PT866720E/pt unknown
- 1996-11-04 JP JP51974597A patent/JP4173914B2/ja not_active Expired - Fee Related
- 1996-11-04 EP EP98119160A patent/EP0956862A1/en not_active Withdrawn
- 1996-11-04 CA CA002236163A patent/CA2236163A1/en active Pending
- 1996-11-04 SI SI9630675T patent/SI0866720T1/xx unknown
- 1996-11-04 DE DE69631544T patent/DE69631544T2/de not_active Expired - Lifetime
- 1996-11-04 AT AT96938773T patent/ATE259243T1/de active
- 1996-11-04 CA CA002358862A patent/CA2358862A1/en not_active Abandoned
- 1996-11-04 AT AT02011474T patent/ATE455554T1/de not_active IP Right Cessation
- 1996-11-04 DE DE69638119T patent/DE69638119D1/de not_active Expired - Lifetime
- 1996-11-04 EP EP96938773A patent/EP0866720B1/en not_active Expired - Lifetime
- 1996-11-04 IL IL12444296A patent/IL124442A0/xx not_active IP Right Cessation
- 1996-11-04 NZ NZ511617A patent/NZ511617A/en not_active IP Right Cessation
- 1996-11-04 AU AU76074/96A patent/AU7607496A/en not_active Abandoned
- 1996-11-04 NZ NZ527007A patent/NZ527007A/en not_active IP Right Cessation
- 1996-11-15 ZA ZA969605A patent/ZA969605B/xx unknown
-
1998
- 1998-05-20 MX MX9803992A patent/MX9803992A/es not_active IP Right Cessation
-
1999
- 1999-01-05 IL IL127926A patent/IL127926A/en not_active IP Right Cessation
-
2000
- 2000-06-23 AU AU42652/00A patent/AU763755B2/en not_active Ceased
- 2000-06-23 AU AU42653/00A patent/AU763769B2/en not_active Ceased
-
2001
- 2001-11-19 JP JP2001352728A patent/JP4227325B2/ja not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008150369A (ja) * | 1997-04-17 | 2008-07-03 | Amgen | 安定かつ活性なヒトOBタンパク質と抗体Fc鎖とのコンジュゲートを含む組成物および方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000500492A (ja) | Ob蛋白組成物を用いる非脂肪組織重増加方法 | |
US7718400B2 (en) | Methods of increasing lean tissue mass using OB protein compositions | |
JP4173913B2 (ja) | Obタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法 | |
DE69737266T2 (de) | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren | |
JP2001501177A (ja) | Obタンパク質受容体をアップレギュレートすることによりobタンパク質に対する個体の感受性を増加させる方法 | |
CN113880915B (zh) | 用于修复黏膜损伤或皮肤创伤的多肽及其应用 | |
JP2002522512A (ja) | デキストラン−レプチン結合体、医薬組成物および関連方法 | |
AU2006201747B2 (en) | Methods of Increasing Lean Tissue Mass Using OB Protein Compositions | |
AU2004200516B2 (en) | Methods of Increasing Lean Tissue Mass Using OB Protein Compositions | |
AU2003201360B2 (en) | Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions | |
MXPA99001875A (en) | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070222 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070222 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080205 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20080205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080805 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080815 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120822 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |